Pacific Biosciences Of California (PACB) Cash from Investing Activities Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.42% |
| Dec 31, 2025 | 17.76% |
| Sep 30, 2025 | 18.10% |
| Jun 30, 2025 | 61.08% |
| Mar 31, 2025 | 23.15% |
| Dec 31, 2024 | 80.37% |
| Sep 30, 2024 | 3.25% |
| Jun 30, 2024 | 57.97% |
| Mar 31, 2024 | -23.72% |
| Dec 31, 2023 | -64.58% |
| Sep 30, 2023 | 53.38% |
| Jun 30, 2023 | -58.76% |
| Mar 31, 2023 | -56.42% |
| Dec 31, 2022 | 49.74% |
| Sep 30, 2022 | 61.66% |
| Jun 30, 2022 | -7.19% |
| Mar 31, 2022 | 10.54% |
| Dec 31, 2021 | 58.03% |
| Jun 30, 2021 | -118.94% |
| Mar 31, 2021 | 18.65% |
| Dec 31, 2020 | -34.44% |
| Sep 30, 2020 | -44.81% |
| Jun 30, 2020 | -34.76% |
| Mar 31, 2020 | -40.89% |
| Dec 31, 2019 | -17.70% |
| Sep 30, 2019 | 9.14% |
| Jun 30, 2019 | 112.81% |
| Mar 31, 2019 | 35.89% |
| Dec 31, 2018 | 25.58% |
| Sep 30, 2018 | -64.17% |
| Jun 30, 2018 | 29.95% |
| Mar 31, 2018 | -6.78% |
| Dec 31, 2017 | -19.81% |
| Sep 30, 2017 | -21.03% |
| Jun 30, 2017 | -128.28% |
| Mar 31, 2017 | 14.45% |
| Dec 31, 2016 | -15.84% |
| Sep 30, 2016 | -13.99% |
| Jun 30, 2016 | -29.39% |
| Mar 31, 2016 | 4.92% |
| Dec 31, 2015 | 23.84% |
| Sep 30, 2015 | 50.81% |